“十四五”收官之年,中国创新药出海纪录再刷新!

制药网
Oct 24

“十四五”收官进入倒计时,国产创新药出海纪录再刷新。10月22日,信达生物宣布,其与武田制药就IBI363、IBI343、IBI3001三款核心抗癌疗法达成全球合作。根据协议,三款药物将以不同的形式达成合作。其中,新一代IO基石疗法IBI363(PD-1/IL-2α-bias)与武田制药达成共同开发协议,将在全球范围内共同开发,并在美国共同商业化。据信达生物透露,武田制药将在共同治理和协同一致的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10